Suppr超能文献

肝硬化和慢性肾脏病患者的肝肾联合移植。

Combined liver-kidney transplantation in patients with cirrhosis and chronic kidney disease.

机构信息

Liver Unit, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Catalunya, Spain.

出版信息

Nephrol Dial Transplant. 2010 Jul;25(7):2356-63. doi: 10.1093/ndt/gfq024. Epub 2010 Feb 4.

Abstract

The outcome of patients with cirrhosis and chronic kidney disease treated with combined liver-kidney transplantation (CLKT) is not well known because most series of patients treated with CLKT include not only patients with cirrhosis but also patients with inherited diseases without cirrhosis. To evaluate to what extent the combined kidney transplantation impairs posttransplantation outcome compared to liver transplantation (LT) alone, the outcome of patients with cirrhosis and chronic kidney disease treated with CLKT (n = 20) was compared to that of a group of patients with cirrhosis without chronic kidney disease treated with LT alone matched by age, sex, year of transplantation and severity of cirrhosis (n = 60). The primary end point of the study was survival, and secondary end points were outcome of renal function and complications within 6 months of transplantation. Patients with CLKT had a higher incidence of bacterial infections and transfusion requirements compared to LT patients. The incidence of acute renal failure during the first 6 months was similar, yet the severity of renal failure was greater in patients with CLKT. Hospital and intensive care unit (ICU) stays were longer in the CLKT group. One- and three-year survival probabilities in patients treated with CLKT were 80 and 75% compared to 97 and 88%, respectively, in patients treated with LT. In conclusion, CLKT for patients with cirrhosis and chronic kidney disease is associated with a relatively high frequency of postoperative complications that moderately impairs short-term survival. However, 3-year survival of patients with cirrhosis treated with CLKT is excellent.

摘要

患有肝硬化和慢性肾脏病的患者接受联合肝肾移植(CLKT)的治疗结果尚不清楚,因为大多数接受 CLKT 治疗的患者系列不仅包括肝硬化患者,还包括无肝硬化的遗传性疾病患者。为了评估联合肾移植与单独肝移植(LT)相比在多大程度上影响移植后的结果,我们比较了 20 例接受 CLKT 治疗的肝硬化和慢性肾脏病患者(n=20)与一组年龄、性别、移植年份和肝硬化严重程度匹配的 60 例仅接受 LT 治疗的无慢性肾脏病的肝硬化患者(n=60)的结果。该研究的主要终点是生存,次要终点是肾功能结果和移植后 6 个月内的并发症。与 LT 患者相比,CLKT 患者的细菌感染和输血需求发生率更高。前 6 个月急性肾衰竭的发生率相似,但 CLKT 患者的肾衰竭程度更严重。CLKT 组的住院时间和重症监护病房(ICU)停留时间更长。CLKT 治疗的患者 1 年和 3 年的生存率分别为 80%和 75%,而 LT 治疗的患者分别为 97%和 88%。总之,对于患有肝硬化和慢性肾脏病的患者,CLKT 术后并发症的发生频率相对较高,这会适度影响短期生存。然而,接受 CLKT 治疗的肝硬化患者 3 年生存率非常高。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验